Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report

Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zachou, Maria, Pikramenos, Konstantinos, Panoutsakou, Maria, Lalla, Efthimia, Androutsakos, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839355/
https://www.ncbi.nlm.nih.gov/pubmed/36654618
http://dx.doi.org/10.7759/cureus.32525
_version_ 1784869466298908672
author Zachou, Maria
Pikramenos, Konstantinos
Panoutsakou, Maria
Lalla, Efthimia
Androutsakos, Theodoros
author_facet Zachou, Maria
Pikramenos, Konstantinos
Panoutsakou, Maria
Lalla, Efthimia
Androutsakos, Theodoros
author_sort Zachou, Maria
collection PubMed
description Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve patient suffering from severe Crohn’s disease who developed DILI with a hepatocellular pattern, without jaundice, after two infusions of an IFX biosimilar.
format Online
Article
Text
id pubmed-9839355
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98393552023-01-17 Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report Zachou, Maria Pikramenos, Konstantinos Panoutsakou, Maria Lalla, Efthimia Androutsakos, Theodoros Cureus Internal Medicine Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve patient suffering from severe Crohn’s disease who developed DILI with a hepatocellular pattern, without jaundice, after two infusions of an IFX biosimilar. Cureus 2022-12-14 /pmc/articles/PMC9839355/ /pubmed/36654618 http://dx.doi.org/10.7759/cureus.32525 Text en Copyright © 2022, Zachou et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Zachou, Maria
Pikramenos, Konstantinos
Panoutsakou, Maria
Lalla, Efthimia
Androutsakos, Theodoros
Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title_full Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title_fullStr Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title_full_unstemmed Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title_short Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
title_sort infliximab (ifx)-biosimilar induced drug-induced liver injury (dili): a case report
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839355/
https://www.ncbi.nlm.nih.gov/pubmed/36654618
http://dx.doi.org/10.7759/cureus.32525
work_keys_str_mv AT zachoumaria infliximabifxbiosimilarinduceddruginducedliverinjurydiliacasereport
AT pikramenoskonstantinos infliximabifxbiosimilarinduceddruginducedliverinjurydiliacasereport
AT panoutsakoumaria infliximabifxbiosimilarinduceddruginducedliverinjurydiliacasereport
AT lallaefthimia infliximabifxbiosimilarinduceddruginducedliverinjurydiliacasereport
AT androutsakostheodoros infliximabifxbiosimilarinduceddruginducedliverinjurydiliacasereport

Ejemplares similares